The hexosamine biosynthesis pathway (HBP) branches from glycolysis and forms uridine diphosphate-β-N-acetylglucosamine (UDP-GlcNAc), the moiety for O-linked β-Nacetylglucosamine (O-GlcNAc) posttranslational modifications. An inability to directly measure HBP flux has hindered our understanding of the factors regulating protein O-GlcNAcylation. Our goals in this study were to (i) validate a LC-MS method that assesses HBP flux as UDP-GlcNAc ( 13 C)-molar percent enrichment (MPE) and concentration; and (ii) determine whether glucose availability or workload regulate cardiac HBP flux. For (i), we perfused isolated murine working hearts with [U-13 C6]glucosamine (1, 10, 50 or 100 µM), which bypasses the rate limiting HBP enzyme. We observed a concentration-dependent increase in UDP-GlcNAc levels and MPE, with the latter reaching a plateau of 56.3±2.9%. For (ii), we perfused isolated working hearts with [U-13 C6]glucose (5.5 or 25 mM). Glycolytic efflux doubled with 25 mM [U-13 C6]glucose; however, the calculated HBP flux was similar among the glucose concentrations at approximately 2.5 nmole/g heart protein/min, representing ~0.003-0.006% of glycolysis. Reducing cardiac workload in beating and non-beating Langendorff perfusions had no effect on the calculated HBP flux at approximately 2.3 and 2.5 nmole/g heart protein/min, respectively. To the best of our knowledge, this is the first direct measurement of glucose flux through the HBP in any organ. We anticipate that these methods will enable foundational analyses of the regulation of HBP flux and protein O-GlcNAcylation. Our results suggest that in the healthy ex vivo perfused heart, HBP flux does not respond to acute changes in glucose availability or cardiac workload.
attachment (OGT), and a single enzyme for removal (O-GlcNAcase, OGA). Protein O-GlcNAcylation is a dynamic and ubiquitous process that occurs predominantly in the cytosol and nucleus affecting a diverse array of protein functions and transcriptional events (1) (2) (3) . In the heart, protein O-GlcNAc levels rise in association with various pathologies including hypertrophy, heart failure, and diabetic cardiomyopathy (4) (5) (6) (7) (8) (9) . Acute increases in protein O-GlcNAcylation are reported to be cardioprotective as they promote myocardial recovery during ischemia/reperfusion or trauma-hemorrhage (10) (11) (12) (13) (14) (15) (16) (17) . The impact of prolonged changes in protein O-GlcNAc levels on the myocardium are variable and may depend on the pathological process (18) . Reducing OGT and protein O-GlcNAc levels during pressure overload hypertrophy causes functional decompensation, whereas elevated protein O-GlcNAc levels appears to cause cardiomyopathy during diabetes (4) (5) (6) (7) (8) (9) . Although protein O-GlcNAcylation has important effects in the myocardium and other tissues, our understanding of the factors regulating protein O-GlcNAc levels is limited.
It is commonly stated that 2-3% of glucose is metabolized via the HBP; however, this percentage was estimated from a single study in rat adipocyte cell cultures (19) and its wider relevance is questionable. Moreover, since this estimate is represented as a percentage of total glucose uptake, it is unclear whether this value would be similar between quiescent cells in culture or in metabolically active organs with a greater energy requirement, such as the heart. Despite the importance of the HBP, there have been no reports on the flux of glucose through the HBP in any biological system. Nevertheless, the link between glucose and protein O-GlcNAcylation represents a mechanism by which changes in metabolism could directly regulate protein and cellular function.
At the level of fructose-6-phosphate (F6P), metabolized glucose can enter the HBP or continue through glycolysis to generate pyruvate (Figure 1 ). L-glutamine:fructose-6-phosphate amidotransferase (GFAT) is the rate-limiting enzyme in the HBP and uses glutamine to catalyze the conversion of F6P to glucosamine-6phosphate (20) which is subsequently metabolized to UDP-GlcNAc, the end product of the HBP. OGT is sensitive to UDP-GlcNAc concentration making overall protein O-GlcNAc levels responsive to changes in HBP flux (21) . Consequently, it is widely accepted that changes in nutrient availability in general and more specifically glucose regulate HBP flux and protein O-GlcNAc levels; however, the data to directly support this remains surprisingly limited (16, (22) (23) (24) . An inability to assess HBP flux has markedly hindered our understanding of the factors regulating protein O-GlcNAc levels in the heart and other tissues.
Accordingly, the goal of this study was to develop a method for quantifying glucose flux through the HBP. We used the ex vivo perfused working heart model, which is a commonly utilized experimental technique to quantify metabolic fluxes for energy production using 13 carbon ( 13 C)-labeled substrates and subsequent 13 C-isotopomer analysis of the cardiac tissue (25) . We first developed and validated a method for measuring UDP-GlcNAc 13 C-enrichment and concentration using liquid chromatography-mass spectrometry (LC-MS).
We chose LC-MS because of the high sensitivity and precision to assess tissue levels of unlabeled and 13 C-labeled intermediates from both glycolysis and HBP without additional derivatization. Subsequently, we measured glucose flux through the HBP and determined whether altering glucose availability and/or workload affects HBP flux in the isolated perfused heart.
RESULTS

LC-MS method development and characteristics.
Our overall goal was to assess glucose partitioning between the HBP and glycolysis. We aimed to develop a LC-MS method that enables reproducible and quantitative measurements in heart tissue of unlabeled and 13 C-labeled UDP-GlcNAc, which is the final HBP intermediate. In addition, we aimed to assess simultaneously using the same method (i) the tissue level of glutamine as well as that of (ii) unlabeled and 13 C-labeling of intracellular metabolites shared or closely related to the HBP, namely the glycolytic intermediates glucose-6-phosphate (G6P), F6P, and fructose 1,6diphosphate (F1,6dP; the metabolite immediately downstream of the regulator phosphofructokinase step of glycolysis) (see Figure 1) . Figures 2A and  2B shows representative chromatograms for all these unlabeled metabolites in a standard solution (2A) and plus the internal standards of [ 13 C2]UDP-GlcNAc and [ 13 C5-N2]glutamine in a nonperfused heart sample (2B). Table 1 reports LC-Quadrupole Time-of-Flight (LC-QToF) method characteristics, namely m/z and retention times, as well as intra-and inter-day coefficient of variations (%CVs) for the quantitative assessment of unlabeled UDP-GlcNAc and glutamine using their respective labeled internal standard, as well as semi-quantitative assessment of G6P, F6P and F1,6dP using the external standard of [ 13 C2]UDP-GlcNAc. Reported retention times are for heart tissue extracts but note that they do slightly vary between experiments. There was very good reproducibility for all metabolites, as evidenced from the intra-and inter-day %CV, which were all below 15%, except for F1,6dP for which there was more variability (%CV = 27-30%) due to peak tailing. In 50 mg heart tissues, the range of endogenous UDP-GlcNAc concentrations (0.7-3.4 nmol) is well above the limit of quantification (LOQ <0.01 nmol). Excellent linearity was observed for the measured level of all metabolites in the range of tested mg heart tissues (20-70 mg; R 2 >0.94), although %CV values were better at 35 mg heart tissue and above (data not shown). Of note, using this method, the heart tissue level of other HBP intermediates; namely glucosamine-6phosphate, N-acetylglucosamine-6-phosphate, and N-acetylglucosamine-1-phosphate, were below our detection levels. Finally, short-term storage at room temperature of extracted samples resulted in no significant variation changes after 7 days upon vortex and sonication.
Pilot studies identifying heart perfusion conditions for 13 C-labeling of the final HBP intermediate UDP-GlcNAc.
We first tested our LC-MS method for its capacity to accurately assess 13 C-enrichement of UDP-GcNAc as well as G6P, F6P and F1,6dP in tissues from rat heart that had been perfused with 5.5 mM [U-13 C6]glucose (molar % enrichment [MPE] between 25-35%) that were part of a previous study (26) . The M+6 MPE, indicating the percentage of a metabolite generated from the exogenous [U-13 C6]glucose, for G6P; F6P; and F1,6dP were at the expected values of around 25-35% (data not shown). Although there was a robust signal for unlabeled UDP-GlcNAc, the M+6 MPE was <2%, which is near lower detection limits. These results led us to perform additional experiments to validate the LC-MS measurement of 13 C-labeled metabolites, particularly UDP-GlcNAc M+6 MPE, described in detail below, in which we use [U-13 C]labeled glucosamine or glucose (MPE 99%). Figure 2C shows a LC-QToF chromatograms for a representative analysis of a sample from hearts perfused with 10 mM [U-13 C6]glucose (MPE 99%). In this case, the signal intensity for G6P; F6P; and F1,6dP is almost exclusively due to M+6 (MPE: 96-97%); the level of unlabeled G6P, F6P and F16dP is very low. For UDP-GlcNAc, the signal due to M+6 UDP-GlcNAc is still small compared to that of the unlabeled, but the M+6 MPE (12.6%) can now be assessed with precision. Of note, UDP-GlcNAc and uridine-diphosphate-N-acetylgalactosamine (UDP-GalNAc) have similar chemical properties and could not be separated with the chromatographic conditions (described in the Methods section) utilized for the above results. Therefore, as part of our method development, we also assessed the percentage of UDP-GalNAc contributing to the UDP-GlcNAc peak using different chromatographic conditions (described in Methods section) in non-perfused mouse hearts as well as in hearts perfused with [U- 13 C6]glucose (99%). The percentage of UDP-GalNAc to UDP-GlcNAc was similar between perfused and non-perfused hearts (n=4 for each group) on average 11.1 ± 0.8% and 10.3 ± 1.1%, respectively. Figure 3 shows a representative LC-QToF chromatogram for a sample of a heart perfused with 5.5 mM [U-13 C6]glucose (MPE 99%) that shows that the peak of UDP-GlcNAc, which is most abundant and is also predominantly 13 C-labeled (M+6) (From experimental group Beating, see below for details). Given the relatively low level of UDP-GalNAc, we did not separate UDP-GlcNAc and UDP-GalNAc in our experiments and values are reported as UDP-GlcNAc rather than UDP-HexNAc (made up of both UDP-GlcNAc and UDP-GalNAc).
working rat heart perfusions acutely increased total protein O-GlcNAcylation presumably by increasing UDP-GlcNAc synthesis (27) . To test our methods for measuring UDP-GlcNAc M+6 enrichment, we perfused mouse hearts in an ex vivo working mode with unlabeled physiological substrates and varying concentrations (0.001 mM, 0.01 mM, 0.05 mM, or 0.1 mM) of [U-13 C6]glucosamine (MPE=99%) for 30 minutes (see Methods for details). The 0.001 mM and 0.01 mM [U-13 C6]glucosamine were also perfused for 60 minutes.
Cardiac functional parameters ( Table 2 ) during these perfusions are consistent with previous studies from our laboratory (28) (29) (30) (31) .
The +dP/dTmax, a measure of cardiac contractility, was slightly lower with glucosamine concentrations of 0.05 and 0.1 mM versus the other concentrations; however, none of the other functional parameters differed among the groups. We also evaluated the effect of glucosamine concentrations on myocardial total protein O-GlcNAc levels and UDP-GlcNAc concentration. Compared to 0.001 mM, 0.05 mM or 0.1 mM glucosamine increased total protein O-GlcNAc levels although this difference only reached significance (p-value<0.05) with 0.1 mM (p-value was 0.058 with 0.05 mM) ( Figure 4A ). Glucosamine 0.1 mM also augmented UDP-GlcNAc concentration compared to the lower glucosamine concentrations ( Figure  4B ) consistent with our prior study (27) .
As for UDP-GlcNAc M+6 MPE, with the 30 minute perfusions, UDP-GlcNAc M+6 MPE increased proportionally to [U-13 C6]glucosamine concentrations at 0.001, 0.01, and 0.05 mM ( Figure 5A ).
UDP-GlcNAc M+6 MPE approximately doubled with the 60 minute perfusions of 0.001 and 0.01 mM [U-13 C6]glucosamine compared to their respective 30 minute perfusions ( Figure 5B ).
Thus, we demonstrate the ability of our new LC-MS methods to measure UDP-GlcNAc M+6 MPE and tissue concentrations. Further, these results are consistent with glucosamine proportionally altering HBP flux and validate that changes in UDP-GlcNAc M+6 MPE and tissue concentration reflect the rate of UDP-GlcNAc synthesis.
Impact of [U-13 C6]glucose concentrations on energy metabolism and HBP flux.
Our next goal was to determine whether glucose availability regulates HBP flux. To accomplish this, isolated mouse hearts were perfused in a working mode for 10, 20, 30, or 60 minutes with either normal or high concentrations of [U-13 C6]glucose (5.5 mM or 25 mM, MPE=99%) along with unlabeled physiological substrates (see Methods for details). Cardiac function for these perfusions is shown in Table 3 . There were no significant differences in cardiac function except for modest increases in +dP/dTmax at 20 and 30 minutes in the 25 mM [U- 13 C6]glucose group compared to the 5.5 mM group.
The glycolytic rate, defined as the efflux of 13 Figure 6A ). In the 25 mM [U- 13 C6]glucose perfusions, there was a small, albeit non-significant, increase in the relative contribution of exogenous [U-13 C6]glucose to both pyruvate (p=0.081, Figure 6B ) and acetyl-CoA formation for citrate synthesis via pyruvate decarboxylation (PDCglu/CS, p=0.085, Figure 6C ) versus the lower glucose concentration. Pyruvate carboxylation, the anaplerotic reaction whereby pyruvate is carboxylated to form the citric acid cycle intermediate oxaloacetate, was similar between the groups ( Figure 6D ) as was the relative ratio of the exogenous [U-13 C6]glucose undergoing pyruvate carboxylation to pyruvate decarboxylation ( Figure 6E ).
We next evaluated 13 C-labeling of G6P and F6P, which are glycolytic intermediates and precursors for the HBP. G6P M+6 MPE was greater in the 25 mM group than the 5.5 mM group at 10 minutes, but the MPEs were equivalent at all other perfusion durations ( Figure  7A ). G6P M+6 MPE increased in the 5.5 mM group from 30 to 60 minutes. Tissue levels of G6P (relative to the external standard [ 13 C2]UDP-GlcNAc) did not vary over time and were significantly higher in the 25 mM hearts as a group versus the 5.5 mM hearts ( Figure 7B ). F6P is the next intermediate and at branch point between HBP and further glycolysis. F6P M+6 MPE was greater than 90% at the 10-minute perfusion time for both glucose concentrations and stabilized at around 95% by 20 minutes ( Figure  7C ). There were no significant differences in F6P M+6 MPE between glucose concentrations compared at the same perfusion duration and F6P M+6 MPE did not increase with the longer perfusion durations. F6P tissue levels (relative to the external standard [ 13 C2]UDP-GlcNAc) also did not vary over time and were higher in the 25 mM group compared to 5.5 mM ( Figure 7D ). The greater tissue levels of both G6P and F6P in the 25 mM group are consistent with the higher glycolytic rate.
The first glycolytic intermediate following the HBP branch point; F1,6dP; was significantly more 13 C-enriched at 10 minutes in the 25 mM versus 5.5 mM group ( Figure 7E ) but were similar between the glucose concentrations at all other perfusion durations. There was a modest increase (p=0.055) in F1,6dP M+6 MPE for the 5.5 mM group from 10 to 20 minutes. Tissue levels of F1,6dP (relative to the external standard [ 13 C2]UDP-GlcNAc) were similar between the groups and did not vary over time ( Figure 7F ); however, there was a large SEM in both groups likely from the peak tailing of this intermediate (described earlier in Results).
We lastly evaluated flux of [U-13 C6]glucose through the HBP. We determined glutamine tissue levels, the amino acid required for first step of the HBP and found similar levels for all groups and perfusion durations (data not shown). Thus, glutamine levels should not differentially affect the ability of glucose to enter the HBP for any of the experimental groups. We subsequently focused on UDP-GlcNAc, the final product of the HBP. UDP-GlcNAc M+6 MPEs were determined over time in both the 5.5 and 25mM [U-13 C6]glucose concentrations.
UDP-GlcNAc M+6 MPE significantly increased from 10 minutes to 20 minutes in both glucose concentrations ( Figure  8A) ; however, there were no further increases in UDP-GlcNAc M+6 MPE with the longer perfusion durations. UDP-GlcNAc M+6 MPE was higher with 25 mM compared to 5mM [U-13 C6]glucose at 10 minutes; however, there were no differences at any other time points. UDP-GlcNAc tissue concentrations were similar between 5 and 25mM groups regardless of perfusion duration; however, UDP-GlcNAc concentrations were lower at 60 minutes compared to the 20-minute perfusions with the same glucose concentrations ( Figure 8B ). Using the UDP-GlcNAc M+6 MPE and concentrations, we determined the absolute amount of UDP-GlcNAc generated from the exogenous [U-13 C6]glucose, which will hereafter be referred to as the UDP-GlcNAC M+6 concentration. The UDP-GlcNAc M+6 concentration rose significantly from 10 to 20 minutes with both glucose concentrations, then plateaued with the longer perfusion times ( Figure  8C ). To calculate glucose flux through the HBP, we used the 10-and 20-minute perfusion times because total UDP-GlcNAc concentration values were stable between these times. The amount of UDP-GlcNAC M+6 produced between 10 to 20 minutes was calculated to be 24.9 nmoles/ g heart protein with 5.5 mM [U-13 C6]glucose and 24.6 nmoles/g heart protein with 25 mM [U-13 C6]glucose. Thus, the rate of glucose flux through the HBP to UDP-GlcNAc between these time points was approximately 2.5 nmole/g heart protein/min with 5.5 mM glucose and 2.5 nmole/gram protein/minute with 25 mM glucose. As a percentage of glycolysis, HBP flux was approximately 0.006% at 5.5 mM [U-13 C6]glucose and 0.003% at 25 mM [U-13 C6]glucose. Overall, these results show that absolute glucose flux through the HBP remains stable even with increasing the rate of glycolysis.
Impact of reducing cardiac workload and energetic demands on HBP flux.
Flux through the HBP as a percentage of glycolysis was substantially lower than anticipated and the flux rate was unaffected by glucose concentrations. We wondered therefore whether HBP flux was artificially inhibited during working heart perfusions because it is non-energy generating pathway that consumes ATP. Therefore, we tested whether lowering myocardial energetic demands would affect HBP flux by perfusing hearts retrograde into the aorta with [U- 13 C6]glucose and unlabeled physiologic substrates in an unloaded manner (hereafter referred to as the Langendorff mode) while beating (Beating group) or with arrest of ventricular contraction (Nonbeating group).
Cardiac function is shown in Table 4 . Oxygen consumption is a direct measure of energetic demand, and, as expected, it was markedly lower in the Beating group compared to the earlier working heart perfusions and even lower in the Non-beating group. Consistent with this finding, the glycolysis rate was approximately 50% lower in the Non-Beating versus Beating hearts ( Figure  9A ) with values of 4.6±0.5 µmole/gram heart protein/minute (Non-beating) and 10.0±1.3 µmole/gram heart protein/minute (Beating). Compared to the working heart perfusions with a similar glucose concentration (5.5 mM), the glycolytic rate was reduced by 75.6% in the Beating group and 89.4% in the Non-Beating groups.
The relative contribution of [U-13 C6]glucose to production of pyruvate, acetyl-CoA formation for citrate synthesis, and pyruvate carboxylation were also significantly reduced in the Non-Beating versus Beating hearts ( Figure 9B -E).
G6P M+6 MPE was similar between Beating and Non-beating groups throughout the perfusion durations ( Figure 10A ). F6P M+6 MPE exceeded 95% for all perfusion durations ( Figure 10B ). There was a small, but significant, increase in F6P M+6 MPE in the Non-Beating versus Beating groups at 40 minutes (97.7±0.1 versus 96.9±0.2, respectively). The tissue levels of both G6P and F6P (relative to the external standard [ 13 C2]UDP-GlcNAc) were similar between Beating and Nonbeating groups and did not fluctuate over time ( Figures 10C and 10D , respectively).
UDP-GlcNAc M+6 MPE significantly increased from 20 to 30 minutes in both groups; however, the increase from 30 to 40 minutes was only reached significance in the Beating group ( Figure 11A ). Comparing the groups at the same perfusion duration, UDP-GlcNAc M+6 MPE was higher in the Non-Beating versus Beating group at 30 minutes.
UDP-GlcNAc myocardial concentrations were similar between the groups for all perfusion times with the exception of 30 minutes. Overall, UDP-GlcNAc concentrations remained stable from 20 minutes through 40 minutes ( Figure 11B ). The calculated quantity of UDP-GlcNAC M+6 (UDP-GlcNAc M+6 Concentration, Figure 11C ) produced between 20 to 40 minutes was 45.6 and 49.6 nmoles/gram heart protein in the Beating and Non-Beating groups, respectively, and the corresponding estimated glucose flux through the HBP was approximately 2.3 (Beating) and 2.5 (Non-Beating) nmole/gram heart protein/minute. However, as the glycolytic rate differed between the groups, HBP flux as a percentage of glycolysis was approximately 0.05% in the Non-beating group and 0.023% in the beating group. Glutamine concentrations were similar among the groups (data not shown). Overall, these results show that lowering energetic requirements and glycolytic flux did not alter the HBP flux rate.
DISCUSSION
Despite an increasing understanding of the diverse roles that protein O-GlcNAcylation plays in regulating cellular function, the inability to quantify HBP flux has greatly hindered our understanding of the factors controlling protein O-GlcNAc levels. Here we have developed methods for quantifying HBP flux using 13 C-labeled substrates and have validated these methods in the isolated perfused heart with [U-13 C6]glucosamine, which bypassed the rate-limiting enzyme GFAT to directly enter the HBP. To the best of our knowledge, this is the first study to directly measure HBP flux in a metabolically active system such as the perfused heart. While glucosamine perfusions demonstrated the expected increase in relative HBP flux with increasing concentrations, we found that increasing glucose concentrations, despite significantly increasing the rates of glycolysis, had no effect on the rate of UDP-GlcNAc synthesis.
We decided to use LC-MS over other methods for several reasons. First, LC-MS has increased sensitivity to detect low abundance of unlabeled and 13 C-labeled metabolites, especially in comparison to 13 C-magnetic resonance spectroscopy. Second, as opposed to GC-MS, sample derivatization is not necessary with LC-MS to detect the metabolic intermediates of interest in both glycolysis and the HBP. Finally, although high performance liquid chromatography (HPLC) has been used to quantify UDP-GlcNAc (32) this technique cannot separate the various UDP-GlcNAc mass isotopomers generated from [U-13 C6]glucose or other 13 C-labeled substrates. Therefore, HPLC cannot determine the fraction of 13 C-labeled UDP-GlcNAc generated from the 13 Clabeled substrate versus other sources such as unlabeled glucose or glycogen. The method that we have developed using LC-MS enables reproducible and accurate determination of the concentration and 13 C-labeling of UDP-GlcNAc using LC-QTOF. Our method also enables accurate measurements of the 13 C-enrichment of by guest on January 17, 2020 http://www.jbc.org/ Downloaded from the glycolytic intermediates, G6P and F6P as well as their relative tissue concentrations expressed as a ratio to the external standard of [ 13 C2]UDP-GlcNAc. For a precise quantitative assessment of G6P and F6P, one could use internal standards of [U-13 C2]labeled G6P and F6P, which can be custom synthesized albeit at high cost upon special request from some companies. F1,6dP showed more peak tailing than G6P and F6P resulting in more variability in its measurements in some experiments. Peak tailing for sugar phosphates has been previously reported by others (33, 34) . We recently found that it can be circumvented by the addition of Agilent's InfinityLab Deactivator additive (Agilent Technologies; 1 ml/min in solvent A; data not shown). Of note, our method developed using the LC-QToF showed a similar performance using LC-triple quadrupole (LC-QQQ; data not shown), which could then be used as an alternative LC-MS instrument.
We made several noteworthy insights through the application of our new method in the isolated perfused hearts. The first was the need to use ~99% [U-13 C6]glucose MPE in order to reliably detect UDP-GlcNAc M+6, which is a higher [U-13 C6]glucose MPE than typically required to evaluate energy metabolism (26, 35) . The higher [U-13 C6]glucose MPE also resulted in a F6P MPE of >90% within 10 minutes in the working heart perfusions, demonstrating that from this time point onwards that the majority of the glucose entering the HBP pathway originates from exogenous [U-13 C6]glucose. This observation provides a solid rationale for using UDP-GlcNAc M+6 measurements from perfusion durations of 10 minutes and longer for quantifying glucose flux through the HBP. However, it is important to note that UDP-GlcNAc concentrations decreased in the working heart at 60 minutes of perfusion, indicating the importance of absolute quantification for evaluating HBP flux. Additional studies are needed to understand the reason for the decrease in UDP-GlcNAc, which may yield better insights into the regulation of HBP flux. Separation of UDP-GlcNAc and UDP-GalNAc is known to be challenging and this value is frequently reported as UDP-HexNAc (27) . By fine tuning the buffer composition, we were able to separate these metabolites and found that ~90% of the UDP-HexNAc is comprised of UDP-GlcNAc in our studies Due to the high percentage of UDP-GlcNAc, we did not perform this additional step for most of the experiments; however, it would be important to include this step when implementing this technique in new biological systems. It is will also be important to know whether this ratio changes in response to physiological or pathological stresses.
Based on the rates of glycolysis and UDP-GlcNAc synthesis, we found that glucose metabolism via the HBP was only ~0.006% of the glycolytic efflux, which is much lower than the frequently cited estimate of 2-3% of glucose uptake is consumed by the HBP estimated from cultured adipocytes (19) .
It is also widely accepted that increasing glucose availability increases flux through the HBP; however, while increasing [U-13 C6]glucose from 5.5 to 25 mM doubled the rate of glycolysis, the rates of UDP-GlcNAc synthesis were virtually identical at ~2.5 nmole/g heart protein/minute for both groups . This also means that relative to glycolysis, the flux through the HBP decreased from 0.006 to 0.003% with the higher glucose concentration. Thus, absolute myocardial HBP flux was not affected by increased glucose availability, but the relative rate actually decreased.
We were surprised by the low rates of HBP flux and wondered whether because the HBP is non-energy generating pathway that consumes ATP, glucose metabolism via the HBP could be inhibited due to the high energy demands of the working heart perfusions. To address this issue, we quantified glucose metabolism via glycolysis and the HBP in the unloaded Langendorff perfused hearts both Beating and Non-beating. As expected, glycolytic flux and MVO 2 were substantially lower in the Langendorff preparations compared to the working hearts and were decreased further in the Non-beating versus Beating group, consistent with lower energetic demands. However, glucose flux through the HBP were similar to the working heart perfusions at approximately 2.3 nmole/g heart protein/min in the Beating group and 2.5 nmole/g protein/min in the Non-Beating group. Thus, the high energetic demands of the working heart preparation do not appear to account for the relatively low flux of glucose through the HBP.
HBP flux was remarkably consistent across the various glycolytic rates and workloads. Thus, glucose availability does not appear to regulate flux through the HBP under these experimental conditions.
We acknowledge that glucose metabolism via the HBP may be low in the perfused heart due to limitations associated with the nature of this ex vivo preparation which may lack unknown factors that regulate HBP flux or artificially inhibit GFAT activity. Phosphorylation affects GFAT activity (36) and, unfortunately, technical limitations prevented us being able to determine GFAT phosphorylation in the perfused hearts. However, our results raise the possibility the changes in glucose availability do not regulate HBP flux alone. In support of this idea, pressure overload cardiac hypertrophy augments glucose utilization and total protein O-GlcNAc levels; however, Nabeebaccus et al. found that induction of GFAT1 protein by NADPH oxidase-4 was required to increase O-GlcNAc levels in this experimental model (37) . HBP flux could also conceivably be a metabolic sensor for intermediates besides glucose as this pathway also requires glutamine, acetyl-CoA, and ATP. Additional experiments are clearly necessary to determine the factors regulating HBP flux in the heart and other organs using the methods described here.
Although HBP flux was similar in the Langendorff and working heart perfusions, relative glucose utilization for the HBP was higher in Langendorff perfusions at roughly 0.05% (Non-Beating) and 0.023% (Beating); however, these differences were due to the lower glycolytic rates compared to the working heart preparations. Nevertheless, it is worth noting that if the HBP flux was indeed ~2% of the glycolytic rate in our working heart perfusions, then glucose flux via the HBP would be between 860 and 1960 nmoles/gram heart protein/min, for the 5mM and 25 mM groups respectively. Considering that the myocardial UDP-GlcNAc concentration averaged about 425 nmoles/g heart protein, UDP-GlcNAc would completely turn over every 13-30 seconds. We believe that such a rapid turnover of UDP-GlcNAc is unlikely because it would be nearly as fast as myocardial ATP turnover. This finding highlights the limitations of expressing HBP flux relative to the glycolytic rate, particularly in biological systems with high energy demands. Consequently, given the high metabolic rate of the heart, we urge caution in projecting the relative HBP flux values reported here to other organs or cell culture models.
In conclusion, using 13 C-labeled substrates combined with LC-MS we have developed a method to quantify both absolute HBP flux and HBP flux relative to glycolysis in the isolated perfused mouse heart.
Using [U- 13 C6]glucosamine, we were able to demonstrate concentration dependent changes in UDP-GlcNAc M+6 MPE, consistent with increased HBP flux. Surprisingly we found that changing glucose concentration from 5.5 to 25mM had no effect on the rate of UDP-GlcNAc synthesis from exogenous glucose; moreover, this rate did not change over a wide range of workloads. The absolute HBP flux remained at ~2.3-2.5 nmole/g protein/minute regardless of perfusion conditions; however, as a fraction of glycolysis the rate varied from 0.006 to 0.023%, due to changes in the rate of glycolysis. These results indicate that, in the isolated perfused heart, glucose utilization via the HBP relative to glycolysis is much lower than that estimated in cultured adipocytes, and we propose that this is in part due to the high rates of glycolysis and energetic demands of the heart. 
Ex vivo heart perfusions in the working and Landendorff mode.
Working heart experiments were performed as previously described (28) (29) (30) (31) . For these experiments, time 0 began following a five minute stabilization period after starting the working mode perfusion (antegrade left atrial perfusion). For the Langendorff perfusion, heart isolation was similar to the working heart perfusions. These hearts were initially stabilized with approximately 5 minutes of retrograde aortic perfusions with unlabeled metabolic substrates. Subsequently, the perfusion solution was switched to the 13 C-labeled and unlabeled substrates described below with a perfusion pressure of 80 mmHg via a gravity-fed apparatus. A SPR-PV-Catheter (SPR-869 or -839 Millar Pressure-Volume Systems, Millar Instruments, Inc, Houston, TX) inserted into the left ventricle to measure cardiac function. Perfusion solutions. The following perfusion solution was used for the glucosamine perfusions: [U-13 C6]glucosamine at the concentrations noted in the results section (MPE=99%) or unlabeled glucosamine, glucose 5.5 mM, oleate 0.4 mM bound to 0.75% (wt/vol) delipidated bovine serum albumin (BSA), pyruvate 0.2 mM, lactate 1.5 mM, carnitine 50 µM, glutamine 0.5 mM, insulin 50 µU/l mixed in physiologic salt solution (PSS) (31) .
Pilot studies were done to assess [U-13 C6]glucose labeling of the HPB and glycolytic intermediates of interest with hearts perfused in a working mode with the following: 10 mM [U-13 C6]glucose along with PSS, oleate 0.7 mM bound to 3% (wt/vol) delipidated bovine serum albumin, insulin 0.8 nM, pyruvate 0.2 mM, lactate 1.5 mM, carnitine 50 µM, glutamine 0.5 mM, and glucosamine 1 µM. Subsequently, to assess the impact of glucose availability on glucose flux through the HBP, hearts were perfused with [U- 13 C6]glucose (5.5 mM or 25 mM, MPE=99%), along with PSS, oleate 0.7 mM bound to 3% (wt/vol) delipidated bovine serum albumin, insulin 0.8 nM, pyruvate 0.2 mM, lactate 1.5 mM, carnitine 50 µM, glutamine 0.5 mM, and glucosamine 1 µM.
To arrest ventricular contraction in the Non-beating group, the perfusion solution also included blebbistatin (10 µM, Selleck Chemicals, Houston, TX, USA). Western blots. Western blots were performed as previously described on freshly isolated protein from perfused hearts or in vivo isolated controls with the RL-2 antibody to determine total protein O-GlcNAc levels (4, (29) (30) (31) .
We attempted western blots for GFAT1/2 and phosphorylated GFAT1; however, the albumen from the heart perfusions interfered with the signal intensity of these proteins.
MS-based analysis of metabolite concentration and 13 C-enrichment for metabolic flux analysis
Sample collection. Procedures for sample collection and processing for metabolite analysis in perfusates and heart tissues were performed as previously described (25) . Measurements of substrate fluxes relevant for energy production. Previously published studies (25, 38, 39) provide definitions of the 13 C terminology and descriptions for measurements by GC-MS (Agilent 6890N GC coupled to a 5973N MS) and equations for the calculations of flux ratios relevant to substrate selection for energy production through mitochondrial citrate synthesis from the 13 C-enrichment of the acetyl (carbons 4 and 5) and oxaloacetate (carbons 1,2,3, and 6) moiety of citrate. Previous studies have shown that it takes approximately a 30-minute perfusion time to reach steady-state for flux measurements of the citric acid cycle; therefore, these measurements were only made for hearts perfused for 30 minutes or longer. Influent and effluent perfusates were used to assess 13 C-enrichment in lactate and pyruvate arising from cytosolic glycolysis of exogenous [U-13 C6]glucose using GC-MS by a previously published method (25, 38, 39) and this measurement is referred to as the glycolytic rate throughout the manuscript. HBP flux. These techniques will be described in detail as they are new. Freeze-clamped heart tissues were used to assess the concentration and 13 C-labeling of metabolites relevant to the assessment of HPB flux, namely G6P; F6P; F1,6dP; UDP-GlcNAc as well as in some perfusions UDP-GalNAc, using the newly developed and validated LC-MS methods described below. (i) Extraction: Samples of 50 mg freeze-clamped heart tissue powder, which had been pulverized in liquid nitrogen, were deproteinized with a mix of 1 ml of methanol 70%, spiked with 20 µL of the internal standard [ 13 C2] UDP-GlcNAc 0.2 mM (4 nmoles) and [U-13 C5, 15 N2]glutamine (150 nmoles) for 10 minutes on ice and homogenized 45 seconds using a Bead Ruptor 12 homogenizer (Omni International, Kennesaw, GA, USA) with six beads (2.8mm ceramic beads media, Omni International, Kennesaw, GA, USA) at high intensity. Following centrifugation at 12,000 g for 10 minutes at 4 o C, the liquid phase was collected, the pellet was extracted a second time in 450 µL 70% methanol. After vortex and centrifugation, the two liquid phases were combined and filtered thought a 13 mm GD/X 0.45 µm syringe filter (Whatman TM , GE Healthcare Lifesciences, Pittsburgh, PA, USA) and the filters were washed with 1 mL methanol 70%. The combined methanol phases were evaporated under nitrogen until 200 µL and kept at 4 o C overnight. The next morning, samples were centrifuged for 5 minutes at 3000 g and a volume of 2 µL of the upper liquid phase was injected into the LC-MS. (iii) LC-MS separation of UDP-GlcNAc and UDP-GalNAc: UDP-GlcNAc and UDP-GalNAc have similar chemical properties and were not separated using chromatographic conditions described above. To assess the amount of UDP-GalNAc contributing to the UDP-GlcNAc peak, we used the following method: Samples (2 uL) were injected on a 1290 Infinity HPLC quipped with an Agilent Zorbax RX-Sil (4.6 x 150 mm, 5 µm) and coupled with a 6530 accurate LC-QToF (Agilent Technologies; Santa Clara, USA) with a Dual Agilent Jet Stream ESI source. Chromatographic conditions were: temperature was set at 30°C, flow rate started at 0.3 mL/min; and the mobile phase A consisted of 5 mM ammonium acetate and 5 mM ammonium formate in water; and B: acetonitrile. The solvent program was 0-2 min, 95% B; 2-11 min, 95-50% B; 11-17 min, 50% B; 17-18 min, 80-95% B, and then an equilibration time of 7 min. LC-MS operating conditions were: gas source temperature: 290°C; drying gas rate: 11 L/min; sheath gas temperature: 375 o C; sheath gas flow: 12 L/min; nebulizer: 35 psi, capillary voltage: 3500 V; and nozzle voltage: 500 V. Mass spectra were acquired from m/z 130 to 650 in MS scan negative mode. MS scans were collected during 1 sec. Retention time (min) were the following: UDP-GlcNAc: 14.43 and UDP-Gal-NAc 14.58. Using this method, the percent contribution of UDP-GalNAc to UDP-GlcNAc peak was evaluated in [U-13 C6]glucose perfused hearts (n=4) and in control (non-perfused) hearts (n=4). (iv) LC-MS data processing. MS signals were extracted using Mass Hunter Quantitative Analysis version B.07 from Agilent. 13 C-labeling of UDP-GlcNAc, F6P and G6P were quantified by extracting the MS signals corresponding to the M and M+6 ions and expressed as MPE. Tissue concentrations of (i) UDP-GlcNAc and UDP-GalNAc were quantitated using the internal standard [ 13 C2]UDP-GlcNAc and (ii) glutamine using the internal standard of [ 13 C5, 15 N2]glutamine. Tissue levels of G6P, F6P and F1,6dP are expressed as ratios relative to the external standard of [ 13 C2]UDP-GlcNAc. Protein quantification. Hearts develop edema during perfusion.
Further, excess perfusion solution is often frozen with the heart during rapid freeze clamping. Thus, the measured weights of freeze clamped hearts after perfusion are unreliable. To control for this issue, all hearts had their protein quantified by the bicinchoninic acid protein assay method. The protein concentration was used to normalize values of UDP-GlcNAc concentration and glycolytic efflux. Statistical Analysis. All reported values are means ± standard error of the mean (SEM). A two-way, unpaired t-test was used for comparisons of two groups that did not involve multiple time points. For comparisons of multiple groups or two groups with multiple perfusion durations, we utilized either a one-or two-factor ANOVA as appropriate. If the global test for the AVOVA was statistically significant; then we performed follow-up pairwise comparisons between the groups of interest identified a priori by pairwise ttests. Because of the low number of replicates per group in some groups, we did not correct for multiple comparisons because a correction procedure would increase the likelihood of committing a type II error. This approach is consistent with literature for exploratory studies such as ours (40) (41) (42) . Criterion for significance was p < 0.05.
We preformed the statistical analysis using GraphPad Prism version 7.03 (GraphPad Software, San Diego, CA).
Acknowledgments:
The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Conflicts of interest:
The authors declare that they have no conflicts of interest with the content of this article. 
FOOTNOTES
TABLES
